Pharmacokinetic considerations in the treatment of multiple sclerosis with interferon-β.
about
Management of flu-like syndrome with cetirizine in patients with relapsing-remitting multiple sclerosis during therapy with interferon beta: Results of a randomized, cross-over, placebo-controlled pilot study.pVAXhsp65 Vaccination Primes for High IL-10 Production and Decreases Experimental Encephalomyelitis Severity.Personalised medicine for multiple sclerosis care.Antitumor activity of interferon-β1a in hormone refractory prostate cancer with neuroendocrine differentiation.Disulfide-bridging PEGylation during refolding for the more efficient production of modified proteins.
P2860
Pharmacokinetic considerations in the treatment of multiple sclerosis with interferon-β.
description
2015 nî lūn-bûn
@nan
2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Pharmacokinetic considerations in the treatment of multiple sclerosis with interferon-β.
@ast
Pharmacokinetic considerations in the treatment of multiple sclerosis with interferon-β.
@en
type
label
Pharmacokinetic considerations in the treatment of multiple sclerosis with interferon-β.
@ast
Pharmacokinetic considerations in the treatment of multiple sclerosis with interferon-β.
@en
prefLabel
Pharmacokinetic considerations in the treatment of multiple sclerosis with interferon-β.
@ast
Pharmacokinetic considerations in the treatment of multiple sclerosis with interferon-β.
@en
P2093
P2860
P1476
Pharmacokinetic considerations in the treatment of multiple sclerosis with interferon-β.
@en
P2093
Florian Deisenhammer
Harald Hegen
Michael Auer
P2860
P304
P356
10.1517/17425255.2015.1094055
P407
P577
2015-09-30T00:00:00Z